EyeMacular Regeneration, Inc. (EyeMac Regen) develops specialized surgical instruments and platform technologies for patients with end-stage macular disease, particularly age-related macular degeneration (AMD), who have exhausted existing treatment options.

Built on 25 years of research, our work pioneers a novel field we call Incisional Choroidal Surgery (ICS). To translate our findings directly into vitreoretinal surgery, we have developed innovative, practical tools (instruments) that are engineered to integrate seamlessly into existing surgical workflows.

For the 160,000 Americans and 1.2 million people worldwide with advanced AMD and no remaining options, EyeMac Regen offers hope.